Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors

Lung cancer has a high prevalence, with a growing number of new cases and mortality every year. Furthermore, the survival rate of patients with non-small-cell lung carcinoma (NSCLC) is still quite low in the majority of cases. Despite the use of conventional therapy such as tyrosine kinase inhibitor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecules Jg. 27; H. 3; S. 819
Hauptverfasser:	Amelia, Tasia, Kartasasmita, Rahmana Emran, Ohwada, Tomohiko, Tjahjono, Daryono Hadi
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 26.01.2022 MDPI
Schlagworte:	activation Amino acids Animals Apoptosis binding Binding sites Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Drug Design Drug Discovery EGFR Epidermal growth factor ErbB Receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - chemistry ErbB Receptors - metabolism Humans Hydrogen bonds inhibitor kinase Kinases Ligands Lung Neoplasms Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Models, Molecular Mutation Organic chemistry Phosphorylation Protein Conformation Protein Conformation - drug effects Protein Kinase Inhibitors Protein Kinase Inhibitors - chemistry Protein Kinase Inhibitors - pharmacology Proteins QD241-441 Review binding kinase inhibitor activation EGFR
ISSN:	1420-3049, 1420-3049
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!